Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neurodegenerative disorders are linked to amyloid peptide misfolding and deposition.
• Passive immunotherapy, particularly using antibodies targeting amyloid β (Aβ), is a key strategy.
• Current treatments focus on Aβ antibodies, but face challenges in clinical trials.

Purpose of the Study:

• To review the current status of Aβ antibodies in clinical development.
• To discuss challenges encountered during clinical trials of these new biological entities (NBEs).
• To explore strategies for overcoming common side effects, such as amyloid-related imaging abnormalities (ARIAs).

Main Methods:

• Literature review of clinical trials and research on Aβ antibodies.
• Analysis of characteristics, efficacy, and safety profiles of Aβ antibodies.
• Examination of emerging therapeutic approaches, including antibodies targeting modified Aβ peptides.

Main Results:

• Aβ antibodies are central to passive immunotherapy for Alzheimer's disease and related disorders.
• Clinical trials reveal challenges, including the occurrence of ARIAs.
• Targeting post-translationally modified Aβ variants presents a novel therapeutic avenue.

Conclusions:

• Passive immunotherapy with Aβ antibodies holds significant therapeutic potential.
• Addressing side effects like ARIAs is crucial for successful clinical application.
• Targeting modified Aβ peptides offers a promising future direction for developing advanced antibody therapies.